Communiqués UCB SA OTC Markets

Actions

Marché Fermé - OTC Markets Autres places de cotation 21:52:12 16/07/2024			Varia. 5j.	Varia. 1 janv.
77,77 ^USD	-0,71 %		-0,04 %	+78,37 %

03/07	On a dit pas si vite !
24/06	ArgenX tracte le Bel20 après une bonne nouvelle pour Vyvgart

UCB : spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)	28/06	PU
UCB : Financial Reporting Document	26/06	PU
UCB : Financial Reporting Document	26/06	PU
UCB : epilepsy drug BRIVIACT(brivaracetam) approved in Japan for treatment of focal onset seizures	26/06	PU
UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project	20/06	BU
UCB : Financial Reporting Document	15/06	PU
UCB : Financial Reporting Document	13/06	PU
UCB : Acquisition of own shares	31/05	PU
UCB : Commitment to Innovation in Drug Development	29/05	PU
UCB : announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa	23/05	PU
UCB - Acquisition of own shares	20/05	AQ
UCB : Transparency notification Wellington	17/05	PU
UCB : Acquisition of own shares	17/05	PU
UCB - Acquisition of own shares	13/05	AQ
UCB : Acquisition of own shares	10/05	PU
UCB presents final open-label extension F data at International Child Neurology Congress Annual Meeting	09/05	AQ
UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	08/05	PU
UCB : presents final open-label extension FINTEPLA®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	08/05	PU
UCB - Acquisition of own shares	06/05	AQ
UCB : Acquisition of own shares	26/04	PU

Aucun résultat pour cette recherche

UCB : UCB prêt à atteindre de nouveaux sommets

Le 08 mars 2024 à 17:10